Post-earnings recap
Reported
Mon, Aug 1, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which led to a slight increase in stock price by 0.21%. The positive surprise in EPS indicates better-than-anticipated cost management or operational efficiency. However, the lack of revenue figures and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | +11.76% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the quarter's performance, particularly in terms of EPS. They emphasized their commitment to pipeline development.
We are pleased with our progress this quarter.
Our focus remains on advancing our pipeline.